1 December, 2021
The PrIMAVeRa consortium held its Kick-off Meeting on 25 November 2021 marking the official launch of this ambitious endeavor. The project partners 19 organisations spanning 12 countries across the European continent with a budget of €9 million. The ultimate goal of PrIMAVeRa is to develop mathematical models and an epidemiological repository to assess the impact of vaccines and monoclonal antibodies (mAbs) on antimicrobial resistance (AMR) – one of the top ten threats to global health as determined by the World Health Organization (WHO).
The event provided an opportunity to align on the goals and strategies of the project, roles and responsibilities of various partners, as well as to introduce a planned collaboration with COMBINE – a related project under Innovative Medicines Initative’s AMR Accelerator. The latter was presented by Prof. Anders Karlén of Uppsala University, Coordinator of COMBINE.
Attendees were also treated to a keynote lecture from Dr. Mateusz Hasso-Agopsowicz (WHO) “Articulating the role of vaccines in preventing AMR: current progress, remaining challenges,” which provided insight into the current state of WHO’s efforts to combat this evolving, multifaceted threat, and informed selection of potential avenues of investigation under PrIMAVeRa.
Additionally Dr Tek-Ang Lim, representative of the Innovative Medicine Initiative (IMI), also joined, presenting “IMI perspective and expectations” and how it relates the latest IMI-funded project PrIMAVeRa.
European Vaccine Initiative thanks all who attended and made this Kick-off Meeting a success.
We look forward to a strong and healthy collaboration resulting in well-informed strategic implementation of vaccines and mAbs in the battle against AMR.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
This communication reflects the author´s view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.